Immunocine Cancer Center Expands as Demand Grows for Personalized Dendritic Cell TherapyHOUSTON, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Responding to a growing number of patients seeking personalized cancer immunotherapy, Immunocine Cancer Center has opened a second treatment location in Cabo San Lucas, Mexico, expanding access to its patented double-loaded dendritic cell therapy while increasing clinical and laboratory capacity.
More Cancer Patients Are Opting to Preserve Their TumorsNew Tumor-Preservation Service Opens in Arizona, Giving Patients the Opportunity to Preserve Unadulterated Tumor Tissue for Potential Personalized Cancer Immunotherapy
Internationally Recognized Johns Hopkins Oncologist Dr. Stephen J. Noga Joins Immunocine as Chief Medical OfficerVeteran Physician-Scientist and Cellular Therapy Expert to Help Advance the Future of Personalized Cancer Immunotherapy
Immunocine Cancer Center Appoints Vita S. Salsman as Executive DirectorImmunocine Cancer Center today announced the appointment of Vita S. Salsman as Executive Director. Salsman brings more than two decades of experience in cancer immunotherapy, cell therapy manufacturing, and translational medicine to support the organization’s continued growth and advancement of personalized cancer immunotherapy. Salsman has built her career advancing innovative therapies from early scientific discovery through clinical application, with expertise spanning cell therapy manufacturing, clinical operations, quality systems, regulatory strategy, and translational medicine.
